Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
On November 6, 2028, Eric Bednarski resigned from
the board of directors (the “Board”) of MDxHealth SA (the “Company”) effective immediately. The decision of Mr.
Bednarski to resign did not result from any disagreement with the Company on any matters relating to the Company’s operations, policies,
or practices.
As part of a restructuring of its commercial organization,
the Company eliminated the position of Chief Commercial Officer. Accordingly, John Bellano's employment with the Company ended effective
October 23, 2026. The Company's sales and marketing functions now report directly to Michael K. McGarrity, the Company's Chief Executive
Officer.
On November 12, 2026, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1.
This Report on Form 6-K shall be deemed to be
incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-292463 and 333-280606) and Form S-8 (Registration
No. 333-294873) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports
subsequently filed or furnished; provided, however, the information in the attached Exhibit 99.1
is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated
by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise
set forth herein or as shall be expressly set forth by specific reference in such a filing.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Exhibit 99.1
Mdxhealth Reports Third Quarter 2026 Financial
Results
Conference call with Q&A today
at 4:30 PM EST / 22:30 CET
IRVINE, Calif. – November 12, 2026
(GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”),
a leader in urology-focused precision diagnostics, today announced its financial results for the third quarter ended September
30, 2026.
Michael K. McGarrity, CEO of mdxhealth, commented:
“As we communicated in our October preliminary update, our third quarter results reflect a temporary disruption in our commercial
execution due to accelerated turnover within our sales organization. In direct response, we have initiated a restructuring of our commercial
organization to reset our focus and process across our sales, marketing, and client services groups. By eliminating the Chief Commercial
Officer role and effectively splitting our sales and marketing functions – both of which now report directly to me – we have
established a vital check and balance on what had become a vertical operating structure, driving clear delineation and direct accountability
for product strategy and sales execution while enhancing our customer experience.
“We have already made considerable progress
in backfilling and rebuilding our sales team, and we are highly encouraged by the caliber of talent and industry experience we are attracting
to mdxhealth. With selection, development, and retention serving as the foundation of our process through this commercial reset, we expect
to exit the fourth quarter with a fully staffed and well-trained sales organization positioned to return to growth in 2027.
“We are confident that this commercial reset
is both necessary and timely as we continue to advance our landmark PROTECT study with the University of Oxford and prepare to roll out
our strategic AI initiatives in the first half of 2027. Supported by our operating teams’ mandate of ‘Quality First and Customers Always,’
we remain committed to returning to the exemplary level of sales execution that has been the hallmark of our results over the last four
years. Coupled with our proven track record of operating discipline, we are well-positioned to return mdxhealth to sustainable growth
and adjusted EBITDA profitability as we continue to build on our unmatched vertical of clinically actionable precision diagnostics for
our customers and patients in urologic cancers.”
Key Highlights
for the third quarter from continuing operations:
| ● | Revenue
of $22.7 million versus same revenue for the prior year period |
| ● | Operating
loss of $8.1 million compared to $4.4 million for third quarter of 2025, primarily due to increased operating expenses related to the
ExoDx acquisition |
| ● | Net
loss of $12.3 million, an increase of 26% over prior year period |
| ● | Adjusted
EBITDA of ($6.3) million compared to ($0.9) million for the same period last year |
| ● | Tissue-based
(Confirm mdx and GPS mdx) test volume of 11,232, a decrease of 11% over prior year period |
| ● | Liquid-based
(Exo mdx) test volume of 11,792 compared to Select mdx volume of 4,600 for the same period last year |
| ● | Period-end
cash and cash equivalents balance of $31.7 million |
Results exclude Resolve mdx, which
has been discontinued and accounted for as a “discontinued operation” for the current and prior year periods.
Discontinuation
of the Resolve mdx Business
As previously announced in our first quarter 2026
update, the Company made the strategic decision to discontinue the Resolve UTI offering to renew our focus on our core prostate cancer
business. We successfully completed this wind-down in Q2, with the permanent cessation of operations of our wholly-owned subsidiary Delta
Laboratories, LLC and its Plano, Texas laboratory prior to June 30, 2026. Having met the requisite accounting criteria, the Resolve business
is now formally classified as a discontinued operation in accordance with IFRS. As required by these reporting standards, all current
and prior-year financial metrics discussed in this release and related financial statements reflect only our continuing core operations,
with the historical results of the Resolve business fully excluded.
Financial
review of continuing operations for the three and nine months ended, September 30, 2026 and 2025
| |
Three
months ended September 30 | | |
Nine
months ended September 30 | |
| USD in ’000 (except
per share data) Unaudited | |
2026 | | |
2025
(re-presented*) | | |
%
Change | | |
2026 | | |
2025
(re-presented*) | | |
%
Change | |
| Revenue | |
| 22,711 | | |
| 22,728 | | |
| 0 | % | |
| 73,817 | | |
| 67,685 | | |
| 9 | % |
| Cost
of sales (exclusive of amortization of intangible assets) | |
| (8,675 | ) | |
| (7,966 | ) | |
| 9 | % | |
| (27,222 | ) | |
| (22,404 | ) | |
| 22 | % |
| Gross Profit | |
| 14,036 | | |
| 14,762 | | |
| (5 | )% | |
| 46,595 | | |
| 45,281 | | |
| 3 | % |
| Operating expenses | |
| (22,164 | ) | |
| (19,130 | ) | |
| 16 | % | |
| (67,986 | ) | |
| (55,865 | ) | |
| 22 | % |
| Operating loss | |
| (8,128 | ) | |
| (4,368 | ) | |
| 86 | % | |
| (21,391 | ) | |
| (10,584 | ) | |
| 102 | % |
| Net loss | |
| (12,259 | ) | |
| (9,736 | ) | |
| 26 | % | |
| (31,433 | ) | |
| (25,998 | ) | |
| 21 | % |
| Adjusted EBITDA** | |
| (6,281 | ) | |
| (912 | ) | |
| n/a | | |
| (13,914 | ) | |
| (914 | ) | |
| n/a | |
| Basic
and diluted loss per share | |
| (0.16 | ) | |
| (0.20 | ) | |
| (20 | %) | |
| (0.53 | ) | |
| (0.52 | ) | |
| 2 | % |
| * | Comparative information
has been re-presented to reflect the classification of the Resolve business as a discontinued operation |
| ** | A reconciliation of IFRS to non-IFRS financial measures has
been provided in the tables included in this press release. An explanation of these measures is also included below under the heading
“Non-IFRS Measures” |
Results from continuing operations for the
three months ended September 30, 2026
Revenue was flat compared to the prior year at
$22.7 million. Revenue in the third quarter of 2026 and 2025 was comprised of 79% and 92% from tissue-based tests, respectively.
Gross profit decreased 5% to $14.0 million compared
to $14.8 million for the prior year. Gross margins were 61.8% as compared to 65.0% for the prior year, a reduction of 3.2 percentage points,
primarily attributed to test mix.
Operating loss increased 86% to $8.1 million compared
to $4.4 million for the prior year, driven by increased operating expenses related to the ExoDx acquisition in September 2025.
Net loss increased 26% to $12.3 million compared
to $9.7 million for the prior year, primarily driven by higher operating expenses related to the ExoDx acquisition in September 2025.
Adjusted EBITDA was ($6.3) million compared to
($0.9) million for the same period last year.
A reconciliation of IFRS to non-IFRS financial
measures has been provided in the tables included in this press release. An explanation of these measures is also included below under
the heading “Non-IFRS Disclosure.”
Results from continuing operations for the
nine months ended September 30, 2026
Revenue increased 9% to $73.8 million compared
to $67.7 million for the prior year. Revenue in the first nine months of 2026 and 2025 was comprised of 76% and 95% from tissue-based
tests, respectively.
Gross profit increased 3% to $46.6 million compared
to $45.3 million for the prior year. Gross margins were 63.1% as compared to 66.9% for the prior year, a reduction of 3.8 percentage points,
primarily attributed to test mix.
Operating loss increased 102% to $21.4 million
compared to $10.6 million for the prior year, driven by increased operating expenses related to the ExoDx acquisition in September 2025.
Net loss increased 21% to $31.4 million compared
to $26.0 million for the prior year, primarily driven by higher operating expenses related to the ExoDx acquisition in September 2025.
Adjusted EBITDA was ($13.9) million compared to
($0.9) million for the same period last year.
A reconciliation of IFRS to non-IFRS financial
measures has been provided in the tables included in this press release. An explanation of these measures is also included below under
the heading “Non-IFRS Disclosure.”
Cash and cash equivalents as of September 30,
2026, were $31.7 million.
Conference
Call
Michael K. McGarrity, Chief Executive Officer,
and Ron Kalfus, Interim Chief Financial Officer, will host a conference call and Q&A session today at 4:30 PM EST / 22:30 CET. The
call will be conducted in English and a replay will be available for 30 days.
To participate in the conference call, please
select your phone number below:
United States: 1-800-347-6865
Belgium: 0800 72 519
United Kingdom: 0808 101 1183
Conference ID: MDX3Q26
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1778654&tp_key=d6263296bf
To ensure a timely connection, it is recommended
that users register at least 10 minutes prior to the scheduled
start time.
About mdxhealth
Mdxhealth is a leading precision diagnostics company
that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary
genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer
and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth
and linkedin.com/company/mdxhealth.
Non-IFRS disclosure
In addition to the Company’s financial results
determined in accordance with IFRS, the Company provides adjusted EBITDA and adjusted EBITDA margin, non-IFRS measures that the Company
determines to be useful in evaluating its operating performance. The Company defines adjusted EBITDA as net loss from continuing operations
less interest expense, depreciation and amortization of intangible assets, impairment, share-based compensation, fair-value adjustments,
provision for inventory obsolescence, reduction in force severance costs, ExoDx acquisition expenses, amendments related to the Exact
Sciences earnout, income tax benefit (expense), and other financial and non-cash expenses. Management believes that presentation of non-IFRS
financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating
results and comparison of operating results across reporting periods. Adjusted EBITDA margin is calculated as adjusted EBITDA divided
by total revenue. The Company uses this non-IFRS financial information to establish budgets, manage the Company’s business, and
set incentive and compensation arrangements. However, non-IFRS financial information is presented for supplemental information purposes
only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented
in accordance with IFRS. For example, non-IFRS adjusted EBITDA excludes a number of expense items that are included in net loss. As a
result, positive adjusted EBITDA may be achieved while a significant net loss persists. The Company’s presentation of expected non-IFRS
adjusted EBITDA is a forward-looking statement about the Company’s future financial performance. This non-IFRS measure includes
adjustments like share-based compensation, debt extinguishment costs, fair-value adjustments related to contingent considerations that
are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. Additionally,
management does not forecast many of the excluded items for internal use. Information reconciling forward-looking non-IFRS measures to
IFRS measures is therefore not available without unreasonable effort and is not provided. The occurrence, timing, and amount of any of
the items excluded from IFRS to calculate non-IFRS could significantly impact the Company’s IFRS results.
Forward-Looking Statement: This
press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the
market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,”
“potential,” “aim,” “explore,” “forward,” “future,” and “believes”
as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding
the Company’s unaudited financial results for the third quarter of 2026; expected future operating results; our strategies, positioning,
resources, capabilities, market opportunities and expectations for future events or performance; and the anticipated timing and benefits
of our organizational changes and strategic initiatives. Such statements and estimates are based on assumptions and assessments of known
and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult
to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples
of forward-looking statements include, among others, statements we make regarding expected future operating results, product development
efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that
could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include,
among others, the following: our ability to successfully and profitably market our products; our ability to recruit, train and retain
qualified sales personnel and the time required for new sales personnel to reach full productivity the acceptance of our products and
services by healthcare providers; our ability to achieve and maintain adequate levels of coverage or reimbursement for our current and
future solutions we commercialize or may seek to commercialize; the willingness of health insurance companies and other payers to cover
our products and services and adequately reimburse us for such products and services; changes in payer claims reimbursement practices
and MDxHealth estimates regarding collection amounts for tests; the results of recoupment decisions and related appeals; the impacts and
effectiveness of exiting from discontinued operations; our ability to obtain and maintain regulatory approvals and comply with applicable
regulations; timing, progress and results of our research and development programs; the period over which we estimate our existing cash
will be sufficient to fund our future operating expenses and capital expenditure requirements; our ability to remain in compliance with
financial covenants made to and make scheduled payments to our creditors; the possibility that the anticipated benefits from our business
acquisitions like our acquisition of the ExoDx and GPS prostate cancer businesses will not be realized in full or at all or may take longer
to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties
are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities
and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to
reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement
is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase
of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any
applicable U.S. securities laws.
NOTE: The mdxhealth logo, mdxhealth,
Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS mdx, Exosome Diagnostics, ExosomeDx, Exo mdx, ExoDx, ExoDx Prostate
Intelliscore (EPI), and Monitor mdx are trademarks or registered trademarks of MDxHealth SA and its affiliates. The GPS test was formerly
known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as
Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype
DX trademark and all other trademarks and service marks, are the property of their respective owners.
CONDENSED UNAUDITED CONSOLIDATED
STATEMENT OF PROFIT OR LOSS
| | |
Three months ended | | |
Nine months ended | |
| | |
September 30, | | |
September 30, | |
| | |
| | |
2025 | | |
| | |
2025 | |
| Thousands of $ (except per share data) | |
2026 | | |
(re-presented*) | | |
2026 | | |
(re-presented*) | |
| –Continuing operations– | |
| | |
| | |
| | |
| |
| Revenues | |
| 22,711 | | |
| 22,728 | | |
| 73,817 | | |
| 67,685 | |
| Cost of sales (exclusive of amortization of intangible assets) | |
| (8,675 | ) | |
| (7,966 | ) | |
| (27,222 | ) | |
| (22,404 | ) |
| Gross profit | |
| 14,036 | | |
| 14,762 | | |
| 46,595 | | |
| 45,281 | |
| Research and development expenses | |
| (2,406 | ) | |
| (2,006 | ) | |
| (6,535 | ) | |
| (6,353 | ) |
| Selling and marketing expenses | |
| (11,693 | ) | |
| (9,458 | ) | |
| (34,497 | ) | |
| (27,274 | ) |
| General and administrative expenses | |
| (7,485 | ) | |
| (7,211 | ) | |
| (23,720 | ) | |
| (19,110 | ) |
| Amortization of intangible assets | |
| (1,246 | ) | |
| (1,289 | ) | |
| (3,759 | ) | |
| (3,915 | ) |
| Other operating (expense) income, net | |
| 666 | | |
| 834 | | |
| 525 | | |
| 787 | |
| Operating loss | |
| (8,128 | ) | |
| (4,368 | ) | |
| (21,391 | ) | |
| (10,584 | ) |
| Financial income | |
| 1,037 | | |
| 502 | | |
| 2,409 | | |
| 1,371 | |
| Financial expenses | |
| (5,168 | ) | |
| (5,876 | ) | |
| (12,451 | ) | |
| (17,070 | ) |
| Loss before income tax | |
| (12,259 | ) | |
| (9,742 | ) | |
| (31,433 | ) | |
| (26,283 | ) |
| Income tax benefit | |
| 0 | | |
| 6 | | |
| 0 | | |
| 285 | |
| Loss from continuing operations | |
| (12,259 | ) | |
| (9,736 | ) | |
| (31,433 | ) | |
| (25,998 | ) |
| –Discontinued operations– | |
| | | |
| | | |
| | | |
| | |
| Loss from discontinued operations, net of tax | |
| (2,054 | ) | |
| 1,726 | | |
| (3,279 | ) | |
| 1,407 | |
| Loss for the period attributable to owners of the parent | |
| (14,313 | ) | |
| (8,010 | ) | |
| (34,712 | ) | |
| (24,591 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Loss per share attributable to owners of the parent | |
| | | |
| | | |
| | | |
| | |
| Basic and diluted loss per share from continuing operations | |
| (0.16 | ) | |
| (0.20 | ) | |
| (0.53 | ) | |
| (0.52 | ) |
| Basic and diluted loss per share from discontinued operations | |
| (0.03 | ) | |
| 0.03 | | |
| (0.06 | ) | |
| 0.02 | |
| Total basic and diluted loss per share | |
| (0.19 | ) | |
| (0.16 | ) | |
| (0.59 | ) | |
| (0.50 | ) |
| * | Comparative information has been re-presented to reflect
the classification of the Resolve business as a discontinued operation. |
CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
| Thousands of $ | |
As of
September 30,
2026 | | |
As of
December 31,
2025 | |
| ASSETS | |
| | |
| |
| Non-current assets | |
| | |
| |
| Goodwill | |
| 39,216 | | |
| 38,948 | |
| Intangible assets | |
| 35,312 | | |
| 39,424 | |
| Property, plant and equipment | |
| 3,019 | | |
| 4,855 | |
| Right-of-use assets | |
| 7,641 | | |
| 9,821 | |
| Financial assets | |
| 2,029 | | |
| 1,496 | |
| Total non-current assets | |
| 87,217 | | |
| 94,544 | |
| | |
| | | |
| | |
| Current assets | |
| | | |
| | |
| Assets held-for-sale | |
| 0 | | |
| 940 | |
| Inventories | |
| 7,171 | | |
| 6,741 | |
| Trade receivables | |
| 11,887 | | |
| 14,675 | |
| Prepaid expenses and other current assets | |
| 1,925 | | |
| 2,021 | |
| Cash and cash equivalents | |
| 31,711 | | |
| 29,032 | |
| Total current assets | |
| 52,694 | | |
| 53,409 | |
| TOTAL ASSETS | |
| 139,911 | | |
| 147,953 | |
| | |
| | | |
| | |
| EQUITY | |
| | | |
| | |
| Share capital | |
| 239,028 | | |
| 219,209 | |
| Issuance premium | |
| 153,177 | | |
| 153,177 | |
| Accumulated deficit | |
| (437,746 | ) | |
| (403,034 | ) |
| Share-based compensation | |
| 21,739 | | |
| 19,335 | |
| Translation reserve | |
| (740 | ) | |
| (781 | ) |
| Total equity | |
| (24,542 | ) | |
| (12,094 | ) |
| | |
| | | |
| | |
| LIABILITIES | |
| | | |
| | |
| Non-current liabilities | |
| | | |
| | |
| Loans and borrowings | |
| 96,849 | | |
| 76,197 | |
| Lease liabilities | |
| 7,034 | | |
| 8,509 | |
| Other non-current financial liabilities | |
| 19,279 | | |
| 25,807 | |
| Total non-current liabilities | |
| 123,162 | | |
| 110,513 | |
| | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Loans and borrowings | |
| 0 | | |
| 0 | |
| Lease liabilities | |
| 1,707 | | |
| 1,898 | |
| Trade payables | |
| 12,140 | | |
| 10,330 | |
| Other current liabilities | |
| 7,121 | | |
| 6,741 | |
| Other current financial liabilities | |
| 20,323 | | |
| 30,565 | |
| Total current liabilities | |
| 41,291 | | |
| 49,534 | |
| Total liabilities | |
| 164,453 | | |
| 160,047 | |
| TOTAL EQUITY AND LIABILITIES | |
| 139,911 | | |
| 147,953 | |
CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS
| Thousands of $ | |
| | |
| |
| For the nine months ended September 30, | |
2026 | | |
2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | |
| | |
| |
| Operating loss | |
| (22,624 | ) | |
| (9,146 | ) |
| Depreciation | |
| 3,189 | | |
| 2,828 | |
| Amortization of intangible assets | |
| 3,775 | | |
| 3,939 | |
| Impairment | |
| 1,065 | | |
| 0 | |
| Provision for inventory obsolescence | |
| 901 | | |
| 794 | |
| Share-based compensation | |
| 1,608 | | |
| 1,518 | |
| Other non-cash transactions | |
| (664 | ) | |
| (853 | ) |
| Cash used in operations before working capital changes | |
| (12,750 | ) | |
| (920 | ) |
| | |
| | | |
| | |
| Changes in operating assets and liabilities | |
| | | |
| | |
| Increase (-) in inventories | |
| (1,407 | ) | |
| (1,383 | ) |
| Increase (-) in receivables | |
| 1,428 | | |
| (538 | ) |
| Increase (+) decrease (-) in payables | |
| 2,164 | | |
| 274 | |
| Net cash outflow from operating activities | |
| (10,565 | ) | |
| (2,567 | ) |
| | |
| | | |
| | |
| CASH FLOWS FROM INVESTING ACTIVITIES | |
| | | |
| | |
| Purchase of property, plant and equipment | |
| (710 | ) | |
| (1,103 | ) |
| Payment of ExoDx purchase price adjustment | |
| (323 | ) | |
| 0 | |
| Payment to Bio-Techne for share of Innovation Platform sale proceeds | |
| (329 | ) | |
| 755 | |
| Earnout payment (GPS acquisition) | |
| (7,479 | ) | |
| (21,252 | ) |
| Transfer of cash due to deconsolidation of Delta Laboratories | |
| (286 | ) | |
| 0 | |
| Interest received | |
| 537 | | |
| 1,249 | |
| Net cash outflow from investing activities | |
| (8,590 | ) | |
| (20,351 | ) |
| | |
| | | |
| | |
| CASH FLOWS FROM FINANCING ACTIVITIES | |
| | | |
| | |
| Proceeds from issuance of shares, net of transaction costs | |
| 20,000 | | |
| 0 | |
| Proceeds from loan obligation | |
| 19,400 | | |
| 24,250 | |
| Earnout payment (GPS acquisition) | |
| (6,521 | ) | |
| (6,719 | ) |
| Repayment of PPP loan obligation | |
| 0 | | |
| (324 | ) |
| Payment of lease liability | |
| (2,080 | ) | |
| (1,570 | ) |
| Payment of interest | |
| (8,613 | ) | |
| (7,175 | ) |
| Other financial expense | |
| (351 | ) | |
| (344 | ) |
| Net cash inflow from financing activities | |
| 21,835 | | |
| 8,118 | |
| | |
| | | |
| | |
| Net decrease in cash and cash equivalents | |
| 2,680 | | |
| (14,800 | ) |
| | |
| | | |
| | |
| Cash and cash equivalents at beginning of the period | |
| 29,032 | | |
| 46,798 | |
| Effect of exchange rates | |
| (1 | ) | |
| 16 | |
| Cash and cash equivalents at end of the period | |
| 31,711 | | |
| 32,014 | |
UNAUDITED RECONCILIATION OF IFRS TO NON-IFRS FINANCIAL MEASURES
| | |
Three months ended | | |
Nine months ended | |
| | |
September 30, | | |
September 30, | |
| | |
| | |
2025 | | |
| | |
2025 | |
| Thousands of $ | |
2026 | | |
(re-presented*) | | |
2026 | | |
(re-presented*) | |
| | |
| | |
| | |
| | |
| |
| IFRS net loss from continuing operations | |
| (12,259 | ) | |
| (9,736 | ) | |
| (31,433 | ) | |
| (25,998 | ) |
| Amortization of intangible assets | |
| 1,246 | | |
| 1,289 | | |
| 3,759 | | |
| 3,915 | |
| Depreciation expense | |
| 777 | | |
| 827 | | |
| 2,769 | | |
| 2,395 | |
| Impairment | |
| 0 | | |
| 367 | | |
| 0 | | |
| 367 | |
| Interest expense, net | |
| 3,593 | | |
| 2,816 | | |
| 9,944 | | |
| 7,299 | |
| Share-based compensation expense | |
| 441 | | |
| 447 | | |
| 1,608 | | |
| 1,518 | |
| Reduction in force severance costs | |
| 0 | | |
| (16 | ) | |
| 0 | | |
| 335 | |
| Income tax expense | |
| 0 | | |
| (6 | ) | |
| 0 | | |
| (285 | ) |
| ExoDx acquisition expenses | |
| 0 | | |
| 1,566 | | |
| 0 | | |
| 1,566 | |
| Fair value adjustments (1) | |
| 416 | | |
| 2,100 | | |
| (295 | ) | |
| 7,735 | |
| Other adjustments (2) | |
| (495 | ) | |
| (566 | ) | |
| (266 | ) | |
| 239 | |
| Adjusted EBITDA | |
| (6,281 | ) | |
| (912 | ) | |
| (13,914 | ) | |
| (914 | ) |
| * | Comparative information has been re-presented to reflect
the classification of the Resolve business as a discontinued operation. |
| 1) | Primarily related to GPS and ExoDx contingent considerations,
option to pay Bio-Techne and Exact Sciences contingent considerations in shares, and Exact Sciences 5-year warrants |
| 2) | Bank fees and other non-cash expenses |
For more information:
info@mdxhealth.com
LifeSci Advisors (IR & PR)
John Fraunces
Managing Director
Tel: +1 917 355 2395
Jfraunces@lifesciadvisors.com